Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price at other companies

Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
——

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?
Supernus Pharmaceuticals (SUPN) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price of $35.04 in Q1 2026.
How has Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price changed year-over-year?
Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price increased by 13.0% year-over-year, from $31.01 to $35.04.
What is the long-term trend for Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price?
Over 2 years (2023 to 2025), Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average exercise price has grown at a 5.7% compound annual growth rate (CAGR), from $29.2 to $32.63.